Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...

Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under ...

Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Failures at Novartis have prompted U.K. | Failures at Novartis have prompted the U.K. marketing watchdog to warn that “companies should be on high alert” when working with third parties to ...

Besides Shanghai Pharma, Novartis has also been working with China’s state-owned behemoth Sinopharma, which markets Novartis’ Gleevec (also known as Glivec) in the country since 2023.

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

Fortune 500 pharmaceutical company Novartis has agreed to acquire San Diego-based Regulus Therapeutics in a deal potentially worth $1.7 billion. (Novartis) ...

Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs.

Novartis swept a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs.

Novartis, a global innovative medicines company, plans to invest $23 billion over five years in U.S.-based infrastructure, ensuring all key Novartis medicines for U.S. patients will be made in the ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s tariffs on imports.

Novartis Gene Therapies cancels Durham North Carolina jobs project, keeps previous hiring incentive, citing lower growth projections ...